Literature DB >> 23770322

TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?

Yun-shang Piao1, Paddy Wiesenfeld, Robert Sprando, Julia T Arnold.   

Abstract

The inflammatory tissue microenvironment can be an active promoter in preneoplastic cancer lesions. Altered steroid hormone metabolism as induced by the inflammatory microenvironment may contribute to epithelial cancer progression. Dehydroepiandrosterone sulfate (DHEAS) is the most abundant endogenous steroid hormone present in human serum and can be metabolized to DHEA, androgens and/or estrogens in peripheral tissues. We have previously reported that TGFβ1-induced reactive prostate stromal cells increase DHEA metabolism to active androgens and alter prostate cancer cell gene expression. While much of the focus on mechanisms of prostate cancer and steroid metabolism is in the epithelial cancer cells, this study focuses on TGFβ1-induced effects on DHEA metabolic pathways and enzymes in human prostate stromal cells. In DHEA-treated primary prostate stromal cells, TGFβ1 produced time- and dose-dependent increases in metabolism of DHEA to androstenedione and testosterone. Also TGFβ1-treated prostate stromal cells exhibited changes in the gene expression of enzymes involved in steroid metabolism including up-regulation of 3β hydroxysteroid dehydrogenase (HSD), and down-regulation of 17βHSD5, and 17βHSD2. These studies suggest that reactive prostate stroma and the inflammatory microenvironment may contribute to altered steroid metabolism and increased intratumoral androgens. Published by Elsevier Ltd.

Entities:  

Keywords:  17HSD2 or 17HSD5; 17β-hydroxysteroid dehydrogenase type 2 or type 5; 4-dione; 5-diol; 5α-androstanedione; 6S; A-dione; ANOVA; AR; Androstenedione; DHEA; DHEA sulfate; DHEAS; DHT; DMEM; Dulbecco's modified Eagles media; E1; E2; ELISA; FBS; HSD; PrSC; Reactive prostate stroma; S.E.M.; Steroid metabolism; T; TGFβ1; Testosterone; analysis of variance; androgen receptor; androstenediol; androstenedione; cancer-derived primary stromal cells; dehydroepiandrosterone; dihydrotestosterone; enzyme-linked immunosorbent assay; estradiol; estrone; fetal bovine serum; hydroxysteroid dehydrogenase; normal primary prostate stromal cells; standard error of the mean; testosterone; transforming growth factorβ-1

Mesh:

Substances:

Year:  2013        PMID: 23770322      PMCID: PMC3839662          DOI: 10.1016/j.jsbmb.2013.05.016

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  43 in total

1.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  The reactive stroma microenvironment and prostate cancer progression.

Authors:  David A Barron; David R Rowley
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

3.  Effect of transforming growth factor-beta1, insulin-like growth factor-I and insulin-like growth factor-II on cell growth and oestrogen metabolism in human breast cancer cell lines.

Authors:  S F Wong; K Reimann; L C Lai
Journal:  Pathology       Date:  2001-11       Impact factor: 5.306

4.  Steroid sulfate sulfatase in human benign prostatic hyperplasia: characterization and quantification of the enzyme in epithelium and stroma.

Authors:  H Klein; T Molwitz; W Bartsch
Journal:  J Steroid Biochem       Date:  1989-08       Impact factor: 4.292

5.  5 alpha-reductase-catalyzed conversion of testosterone to dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids.

Authors:  Hung Pham; Vincent A Ziboh
Journal:  J Steroid Biochem Mol Biol       Date:  2002-11       Impact factor: 4.292

6.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.

Authors:  A Latil; I Bièche; D Vidaud; R Lidereau; P Berthon; O Cussenot; M Vidaud
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

Authors:  Jennifer A Tuxhorn; Gustavo E Ayala; Megan J Smith; Vincent C Smith; Truong D Dang; David R Rowley
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

8.  Corticotropin regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5----4-isomerase in ovine adrenocortical cells: inhibition by transforming growth factor beta.

Authors:  D Naville; W E Rainey; J I Mason
Journal:  Mol Cell Endocrinol       Date:  1991-03       Impact factor: 4.102

9.  Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.

Authors:  J Geller
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

Review 10.  Intracrinology.

Authors:  F Labrie
Journal:  Mol Cell Endocrinol       Date:  1991-07       Impact factor: 4.102

View more
  3 in total

Review 1.  Molecular pathways and targets in prostate cancer.

Authors:  Emma Shtivelman; Tomasz M Beer; Christopher P Evans
Journal:  Oncotarget       Date:  2014-09-15

2.  Inhibition of Nox4-dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal-mediated protumorigenic interactions.

Authors:  Natalie Sampson; Elena Brunner; Anja Weber; Martin Puhr; Georg Schäfer; Cedric Szyndralewiez; Helmut Klocker
Journal:  Int J Cancer       Date:  2018-03-01       Impact factor: 7.396

Review 3.  Genome-wide crosstalk between steroid receptors in breast and prostate cancers.

Authors:  Ville Paakinaho; Jorma J Palvimo
Journal:  Endocr Relat Cancer       Date:  2021-07-22       Impact factor: 5.678

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.